While A549 TIS lung cancer cells induced by bleomycin and alisertib exhibited exquisite sensitivity to BCL-xL-targeting agents, palbociclib- and doxorubicin-TIS A549 cancer cells were relatively resistant, correlating with their reduced overall priming. This evidence concerns the gene BCL2L1 and lung cancer.